• Login
  • Register
Nairametrics
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Nairalytics
    • Macro-Economic News
    • Research Analysis
    • Budget
    • Public Debt
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
No Result
View All Result
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Nairalytics
    • Macro-Economic News
    • Research Analysis
    • Budget
    • Public Debt
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
No Result
View All Result
Nairametrics
No Result
View All Result
Home Business News Coronavirus
Covid-19: AstraZeneca vaccine gets huge boost, produces immune response in elderly, Vaccine, COVID-19: Russia to roll out vaccine in September ahead of the West 

Covid-19: AstraZeneca vaccine gets huge boost, produces immune response in elderly

Pfizer, BioNTech say their Covid-19 vaccine is over 90% effective in phase 3 trial

Chike OlisahbyChike Olisah
3 years ago
in Coronavirus, Spotlight
Share on FacebookShare on TwitterShare on Linkedin

Pfizer Inc had on Monday disclosed that its experimental vaccine which it is jointly developing with BioNTech was more than 90% effective in preventing COVID-19 based on initial data from a large study, in the ongoing phase 3 trials.

This is a major victory in the fight against a pandemic that has killed over 1 million people, negatively impacted on the world’s economy and upended daily life.

READ: Covid-19: AstraZenca drugs aims to be ready for large-scale vaccination this year

This disclosure was made in a statement by the Chairman and Chief Executive Officer of Pfizer, Albert Bourla, on Monday, November 9, 2020.

Pfizer and German partner BioNTech SE are the first drugmakers to show successful data from a large-scale clinical trial of a coronavirus vaccine. The companies said they have so far found no serious safety concerns and expect to seek U.S. emergency use authorization later this month.

If authorized, the number of vaccine doses will initially be limited. Many questions also remain including how long the vaccine will provide protection. However, the news provides hope that other vaccines in development against the novel coronavirus may also prove effective.

READ: COVID-19: US to have enough vaccines for vulnerable Americans by end of 2020

Albert Bourla, in his statement, said, “Today is a great day for science and humanity. We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen.”

He said that the first set of results from the Phase 3 Covid-19 vaccine trial provides the initial evidence of their vaccine’s ability to prevent Covid-19

READ: Airsmat berths artificial intelligence platform to improve farm output

Pfizer expects to seek broad U.S. emergency use authorization of the vaccine for people aged 16 to 85. To do so, it will need to have collected two months of safety data on around half of the study’s roughly 44,000 participants, expected in late November.

Bill Gruber, one of Pfizer’s top vaccine scientists, said in an interview, ‘’I’m near ecstatic. This is a great day for public health and for the potential to get us all out of the circumstances we’re now in.”

READ: NCC grants national roaming services approval to MTN, 9mobile

Pfizer said the interim analysis was conducted after 94 participants in the trial developed COVID-19, examining how many of them received the vaccine versus placebo.

Details later…


Download Nairametrics App for breaking news and market intelligence.
   
Tags: Business NewsCovid-19Pfizer Inc.
Chike Olisah

Chike Olisah

Chike was a banker with over 11 years experience in retail and commercial banking, risk management, treasury portfolio management and relationship management. He also acquired some experience in financial management and do have some special interest in investment analysis and personal finance. He had stints with financial institutions like the former Intercontinental Bank and Fidelity Bank.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *







NM newsletters
Kwakol
Abbey
IMT

Zenth Bank
UBA
Mega Millions

Business News | Stock Market | Money Market | Cryptos | Financial Literacy | SME |

Recent News

  • FG cautions fuel station operators against pump alteration
  • Fuel Subsidy: Reducing unit OPEX in operations will reduce pump prices – Expert 
  • How Africa is becoming an emerging force in the iGaming industry 

Follow us on social media:

Recent News

Petrol price, NNPCL, PMS

FG cautions fuel station operators against pump alteration

September 22, 2023
BIG READ: Low patronage sparks fear of job losses for petrol stations  

Fuel Subsidy: Reducing unit OPEX in operations will reduce pump prices – Expert 

September 22, 2023
  • Download Nairametrics iOS App
  • Download Nairametrics Android App
  • Contact Us
  • Home
  • Exclusives
  • Markets
  • Industries
  • Economy
  • Business News
  • Financial Literacy
  • Opinions

© 2023 Nairametrics

No Result
View All Result
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Nairalytics
    • Macro-Economic News
    • Research Analysis
    • Budget
    • Public Debt
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
  • Login
  • Sign Up

© 2023 Nairametrics

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In